These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 10555385

  • 21. Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
    Karmiris K, Bossuyt P, Sorrentino D, Moreels T, Scarcelli A, Legido J, Dotan I, Naismith GD, Jussila A, Preiss JC, Kruis W, Li AC, Bouguen G, Yanai H, Steinwurz F, Katsanos KH, Subramaniam K, Tarabar D, Zaganas IV, Ben-Horin S, ECCO CONFER investigators.
    J Crohns Colitis; 2015 May; 9(5):382-9. PubMed ID: 25740813
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Treatment of ulcerative colitis.
    Blonski W, Buchner AM, Lichtenstein GR.
    Curr Opin Gastroenterol; 2014 Jan; 30(1):84-96. PubMed ID: 24285003
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Inflammatory bowel disease.
    Podolsky DK.
    N Engl J Med; 2002 Aug 08; 347(6):417-29. PubMed ID: 12167685
    [No Abstract] [Full Text] [Related]

  • 28. [Medical therapy of inflammatory bowel diseases: ulcerative colitis].
    Lakatos L, Lakatos PL.
    Orv Hetil; 2007 Jun 24; 148(25):1163-70. PubMed ID: 17573252
    [Abstract] [Full Text] [Related]

  • 29. [Inflammatory bowel disease].
    Patuto N, Beglinger C.
    Praxis (Bern 1994); 2013 Aug 21; 102(17):1046-52. PubMed ID: 23965717
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Histopathologic diagnosis of the activity of chronic inflammatory bowel disease. Evaluation of the effect of drug treatment. Use of histological scores].
    Geboes K, Desreumaux P, Jouret A, Ectors N, Rutgeerts P, Colombel JF.
    Gastroenterol Clin Biol; 1999 Oct 21; 23(10):1062-73. PubMed ID: 10592879
    [No Abstract] [Full Text] [Related]

  • 36. The therapeutic spectrum of infliximab and tumor necrosis factor immunomodulation in chronic inflammatory diseases.
    Ricart E, Bouma G, Peña AS.
    Drugs Today (Barc); 2002 Nov 21; 38(11):725-44. PubMed ID: 12582457
    [Abstract] [Full Text] [Related]

  • 37. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H, Seksik P, Carrat F, Nion-Larmurier I, Vienne A, Beaugerie L, Cosnes J.
    Gut; 2010 Oct 21; 59(10):1363-8. PubMed ID: 20587545
    [Abstract] [Full Text] [Related]

  • 38. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease.
    de Bie CI, Escher JC, de Ridder L.
    Inflamm Bowel Dis; 2012 May 21; 18(5):985-1002. PubMed ID: 21936033
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Changing paradigm in the management of inflammatory bowel disease].
    Jang BI.
    Korean J Gastroenterol; 2015 May 21; 65(5):268-72. PubMed ID: 25998972
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.